Literature DB >> 27899849

Statin Therapy: Review of Safety and Potential Side Effects.

Satish Ramkumar1, Ajay Raghunath1, Sudhakshini Raghunath1.   

Abstract

BACKGROUND: Hydroxymethyl glutaryl coenzyme A reductase inhibitors, commonly called statins, are some of the most commonly prescribed medications worldwide. Evidence suggests that statin therapy has significant mortality and morbidity benefit for both primary and secondary prevention from cardiovascular disease. Nonetheless, concern has been expressed regarding the adverse effects of long term statin use. The purpose of this article was to review the current medical literature regarding the safety of statins.
METHODS: Major trials and review articles on the safety of statins were identified in a search of the MEDLINE database from 1980 to 2016, which was limited to English articles.
RESULTS: Myalgia is the most common side effect of statin use, with documented rates from 1-10%. Rhabdomyolysis is the most serious adverse effect from statin use, though it occurs quite rarely (less than 0.1%). The most common risk factors for statin-related myopathy include hypothyroidism, polypharmacy and alcohol abuse. Derangement in liver function tests is common, affecting up to 1% of patients; however, the clinical significance of this is unknown. Some statin drugs are potentially diabetogenic and the risk appears to increase in those patients on higher doses. Pitavastatin has not been associated with increased risk of diabetes. Statins have not been proven to increase the risk of malignancy, dementia, mood disorders or acute interstitial nephritis. However, statins do have multiple drug interactions, primarily those which interact with the cytochrome p450 enzyme group.
CONCLUSIONS: Overall, statin drugs appear to be safe for use in the vast majority of patients. However, patients with multiple medical co-morbidities are at increased risk of adverse effects from long-term statin use.

Entities:  

Keywords:  Dyslipidemia; Hypercholesterolemia; Statin

Year:  2016        PMID: 27899849      PMCID: PMC5126440          DOI: 10.6515/acs20160611a

Source DB:  PubMed          Journal:  Acta Cardiol Sin        ISSN: 1011-6842            Impact factor:   2.672


  44 in total

1.  The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study.

Authors:  Jarir Atthobari; Auke H Brantsma; Ron T Gansevoort; Sipke T Visser; Folkert W Asselbergs; Wiek H van Gilst; Paul E de Jong; Lolkje T W de Jong-van den Berg
Journal:  Nephrol Dial Transplant       Date:  2006-05-23       Impact factor: 5.992

2.  Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial.

Authors:  Dick de Zeeuw; Deborah A Anzalone; Valerie A Cain; Michael D Cressman; Hiddo J Lambers Heerspink; Bruce A Molitoris; John T Monyak; Hans-Henrik Parving; Giuseppe Remuzzi; James R Sowers; Donald G Vidt
Journal:  Lancet Diabetes Endocrinol       Date:  2015-02-04       Impact factor: 32.069

3.  Cost-effectiveness and population impact of statins for primary prevention in adults aged 75 years or older in the United States.

Authors:  Michelle C Odden; Mark J Pletcher; Pamela G Coxson; Divya Thekkethala; David Guzman; David Heller; Lee Goldman; Kirsten Bibbins-Domingo
Journal:  Ann Intern Med       Date:  2015-04-21       Impact factor: 25.391

Review 4.  Statin and the risk of renal-related serious adverse events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trials.

Authors:  Sripal Bangalore; Rana Fayyad; G Kees Hovingh; Rachel Laskey; Liffert Vogt; David A DeMicco; David D Waters
Journal:  Am J Cardiol       Date:  2014-04-03       Impact factor: 2.778

5.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

Authors:  Zeljko Reiner; Alberico L Catapano; Guy De Backer; Ian Graham; Marja-Riitta Taskinen; Olov Wiklund; Stefan Agewall; Eduardo Alegria; M John Chapman; Paul Durrington; Serap Erdine; Julian Halcox; Richard Hobbs; John Kjekshus; Pasquale Perrone Filardi; Gabriele Riccardi; Robert F Storey; David Wood
Journal:  Eur Heart J       Date:  2011-06-28       Impact factor: 29.983

6.  Statin Use, Diabetes Incidence and Overall Mortality in Normoglycemic and Impaired Fasting Glucose Patients.

Authors:  M Regina Castro; Gyorgy Simon; Stephen S Cha; Barbara P Yawn; L Joseph Melton; Pedro J Caraballo
Journal:  J Gen Intern Med       Date:  2016-02-05       Impact factor: 5.128

7.  Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.

Authors:  David Preiss; Sreenivasa Rao Kondapally Seshasai; Paul Welsh; Sabina A Murphy; Jennifer E Ho; David D Waters; David A DeMicco; Philip Barter; Christopher P Cannon; Marc S Sabatine; Eugene Braunwald; John J P Kastelein; James A de Lemos; Michael A Blazing; Terje R Pedersen; Matti J Tikkanen; Naveed Sattar; Kausik K Ray
Journal:  JAMA       Date:  2011-06-22       Impact factor: 56.272

8.  A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.

Authors:  Jun Sasaki; Yoshihiko Ikeda; Tadanobu Kuribayashi; Keizou Kajiwara; Sadatoshi Biro; Kyosuke Yamamoto; Masato Ageta; Syozou Kobori; Tetsunori Saikawa; Takatoshi Otonari; Suminori Kono
Journal:  Clin Ther       Date:  2008-06       Impact factor: 3.393

9.  Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network.

Authors:  Mark W Russo; Jay H Hoofnagle; Jiezhun Gu; Robert J Fontana; Huiman Barnhart; David E Kleiner; Naga Chalasani; Herbert L Bonkovsky
Journal:  Hepatology       Date:  2014-05-13       Impact factor: 17.425

10.  Statin use and all-cancer survival: prospective results from the Women's Health Initiative.

Authors:  Ange Wang; Aaron K Aragaki; Jean Y Tang; Allison W Kurian; JoAnn E Manson; Rowan T Chlebowski; Michael Simon; Pinkal Desai; Sylvia Wassertheil-Smoller; Simin Liu; Stephen Kritchevsky; Heather A Wakelee; Marcia L Stefanick
Journal:  Br J Cancer       Date:  2016-06-09       Impact factor: 7.640

View more
  68 in total

1.  Do Statins Increase the Risk of Esophageal Conditions? Findings from Four Propensity Score-Matched Analyses.

Authors:  Ioana Smith; Robert Schmidt; Ethan A Halm; Ishak A Mansi
Journal:  Clin Drug Investig       Date:  2018-02       Impact factor: 2.859

2.  Assessing the Relationship Between American Heart Association Atherosclerotic Cardiovascular Disease Risk Score and Coronary Artery Imaging Findings.

Authors:  Ying Li; Guangming Zhu; Victoria Ding; Bin Jiang; Robyn L Ball; Neera Ahuja; Fatima Rodriguez; Dominik Fleischmann; Manisha Desai; David Saloner; Luca Saba; Max Wintermark; Jason Hom
Journal:  J Comput Assist Tomogr       Date:  2018 Nov/Dec       Impact factor: 1.826

3.  The Association Between Polypharmacy and Physical Function in Older Adults: a Systematic Review.

Authors:  Andreas Katsimpris; Jacob Linseisen; Christa Meisinger; Konstantinos Volaklis
Journal:  J Gen Intern Med       Date:  2019-06-25       Impact factor: 5.128

4.  Statins Perturb Gβγ Signaling and Cell Behavior in a Gγ Subtype Dependent Manner.

Authors:  Mithila Tennakoon; Dinesh Kankanamge; Kanishka Senarath; Zehra Fasih; Ajith Karunarathne
Journal:  Mol Pharmacol       Date:  2019-02-14       Impact factor: 4.436

5.  Manifesting heterozygotes in McArdle disease: a myth or a reality-role of statins.

Authors:  Judit Núñez-Manchón; Alfonsina Ballester-Lopez; Emma Koehorst; Ian Linares-Pardo; Daniëlle Coenen; Ignacio Ara; Carlos Rodriguez-Lopez; Alba Ramos-Fransi; Alicia Martínez-Piñeiro; Giuseppe Lucente; Miriam Almendrote; Jaume Coll-Cantí; Guillem Pintos-Morell; Alejandro Santos-Lozano; Joaquin Arenas; Miguel Angel Martín; Mauricio de Castro; Alejandro Lucia; Alfredo Santalla; Gisela Nogales-Gadea
Journal:  J Inherit Metab Dis       Date:  2018-06-20       Impact factor: 4.982

Review 6.  Aspirin, Statins, and Primary Prevention: Opportunities for Shared Decision Making in the Face of Uncertainty.

Authors:  Amit Jhaveri; Rachel A Sibley; Erica S Spatz; John Dodson
Journal:  Curr Cardiol Rep       Date:  2021-05-07       Impact factor: 2.931

7.  Lovastatin protects against cisplatin-induced hearing loss in mice.

Authors:  Katharine Fernandez; Katie K Spielbauer; Aaron Rusheen; Lizhen Wang; Tiffany G Baker; Stephen Eyles; Lisa L Cunningham
Journal:  Hear Res       Date:  2020-02-06       Impact factor: 3.208

8.  Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe.

Authors:  Kamlesh Khunti; Mark D Danese; Lucie Kutikova; David Catterick; Francisco Sorio-Vilela; Michelle Gleeson; Sreenivasa Rao Kondapally Seshasai; Jack Brownrigg; Kausik K Ray
Journal:  JAMA Netw Open       Date:  2018-12-07

Review 9.  The impact of statins on physical activity and exercise capacity: an overview of the evidence, mechanisms, and recommendations.

Authors:  Allyson M Schweitzer; Molly A Gingrich; Thomas J Hawke; Irena A Rebalka
Journal:  Eur J Appl Physiol       Date:  2020-04-04       Impact factor: 3.078

10.  Crystal structures of human NSDHL and development of its novel inhibitor with the potential to suppress EGFR activity.

Authors:  Dong-Gyun Kim; Sujin Cho; Kyu-Yeon Lee; Seung-Ho Cheon; Hye-Jin Yoon; Joo-Youn Lee; Dongyoon Kim; Kwang-Soo Shin; Choong-Hyun Koh; Ji Sung Koo; Yuri Choi; Hyung Ho Lee; Yu-Kyoung Oh; Yoo-Seong Jeong; Suk-Jae Chung; Moonkyu Baek; Kwan-Young Jung; Hyo Jin Lim; Hyoun Sook Kim; Sung Jean Park; Jeong-Yeon Lee; Sang Jae Lee; Bong-Jin Lee
Journal:  Cell Mol Life Sci       Date:  2020-03-05       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.